Veritas In Silico Files Patent for New lncRNA Targeting Medication

TOKYO, Aug 03 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) filed a joint patent application with Mitsubishi Gas Chemical Co., Ltd.

For a novel antisense oligonucleotide (ASO) targeting long non-coding RNA (lncRNA) H19. The application, numbered 2026-179,989, aims to develop a medication addressing cancers associated with abnormal lncRNA H19 activity. The development timeline spans 8 to 10 years, with clinical trials planned to commence once sufficient patient populations are identified. The company's proprietary drug discovery platform, aibVIS, enables simultaneous exploration of small molecule and nucleic acid-based therapies.

By leveraging advanced technologies, Veritas In Silico seeks to create high-activity ASOs without complex chemical modifications, potentially reducing side effects while enhancing therapeutic efficacy. The proposed treatment could complement existing cancer therapies and minimize adverse reactions in normal cells due to low expression levels of lncRNA H19. This patent filing aligns with Veritas In Silico’s strategic goals, contributing to their key performance indicators (KPIs) for pipeline creation in fiscal year 2026. Research and development expenses related to this project are included in previously disclosed forecasts for the fiscal year ending December 2026, with no anticipated changes to those projections.